panErbB pCAR

N/A

Report date: 2025/01/26 17:32:34

Base Information

Drug NamepanErbB pCAR
Drug Alias NameAnti-panErbB CAR T-cell therapy (Leucid Bio)Anti-ErbB CAR T-cell therapy (Leucid Bio)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor tyrosine-protein kinase erbB modulators
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLeucid Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLeucid Bio Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A